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With its ability to show the interactions between drug-target proteins and small-
molecule ligands, X-ray crystallography is an essential tool in drug-discovery
programmes. However, its usefulness can be limited by crystallization artifacts
or by the data resolution, and in particular when assumptions of unimodal
binding (and isotropic motion) do not apply. Discrepancies between the
modelled crystal structure and the physiological range of structures generally
prevent quantitative estimation of binding energies. Improved crystal structure
resolution will often not aid energy estimation because the conditions which
provide the highest rigidity and resolution are not likely to reflect physiological
conditions. Instead, strategies must be employed to measure and model
flexibility and multiple binding modes to supplement crystallographic informa-
tion. One useful tool is the use of anomalous dispersion for small molecules that
contain suitable atoms. Here, an analysis of the binding of the kinase inhibitor
H-89 to protein kinase A (PKA) is presented. H-89 contains a bromobenzene
moiety that apparently binds with multiple conformations in the kinase ATP
pocket. Using anomalous dispersion methods, it was possible to resolve these
conformations into two distinct binding geometries.
1. Introduction
Apart from the approved drug Fasudil (HA-1077), H-89 is one of the
most prominent representatives of the ‘H-series’ of kinase inhibitors,
a set of ATP-competitive isoquinoline sulfonamides (Chijiwa et al.,
1990; Hidaka et al., 1984; Ono-Saito et al., 1999; Fig. 1). H-89 was
developed and reported to be selective towards the catalytic subunit
of cAMP-dependent protein kinase, also known as protein kinase A
(PKA). Despite its misregulation in certain types of cancer, PKA is
usually considered to be an ‘antitarget’ in drug development owing to
the ubiquitous and essential nature of the cellular processes that it
regulates. Hence, the use of H-89 has largely remained confined to
academic research. In contrast, the Rho kinase-targeting inhibitor
Fasudil was approved in Japan in 1995 for the prevention of cerebral
vasospasm in patients with subarachnoid haemorrhage and was found
to potentially be useful to enhance the memory and improve the
prognosis of Alzheimers patients (Huentelman et al., 2009). However,
H-89 became particularly popular for in vitro studies requiring the
absence of PKA activity or on the regulatory role of PKA itself. It is
still used frequently, but now in the context of recent studies that have
shown H-89 to be a rather general AGC kinase inhibitor (Davies
et al., 2000; Lochner & Moolman, 2006). While one barrier to the
development of H-series compounds as drugs may be the inhibition
of PKA, H-89 has also proven to be useful in drug-design projects.
The H-89 scaffold has provided the basis for the design of new
compounds with selectivity towards protein kinase B (PKB/Akt;
Caldwell et al., 2008; Collins et al., 2006; Reuveni et al., 2002), which
is structurally similar to PKA (Gassel et al., 2003) and remains an
important drug target (Cheng et al., 2005; Wu & Hu, 2010).
2. Materials and methods
2.1. Protein production, purification and crystallization
The full-length human catalytic subunit  of PKA (GenBank
accession No. NP_002721) was expressed in Escherichia coli BL21
(DE3)-RIL cells (Stratagene) from a construct based on the vector
pT7-7 in auto-induction medium (Studier, 2005) over a period of
approximately 20 h at 297 K. The procedures used for the purification
of PKA followed previously published protocols (Engh et al., 1996).
Cocrystallization of PKA and H-89 was carried out in hanging
drops at 277 K. Drops consisting of 10 mg ml1 protein, 25 mM bis-
tris/MES pH 6.9, 50 mM KCl, 1.5 mM octanoyl-N-methylglucamide,
1 mM ‘protein kinase inhibitor’ peptide (PKI; 5TTYADFIASGR-
TGRRNAIHD24) and 5 mM H-89 (added from a 100 mM methanol
stock) were equilibrated against 12–22%(v/v) methanol. For data
collection, crystals were transferred into 30% 2-methyl-2,4-pentane-
diol and flash-cooled.
2.2. Diffraction data collection and data processing
The diffraction of a cooled crystal was measured on beamline ID29
at the European Synchrotron Radiation Facility (ESRF; Grenoble,
France). The wavelength of 0.91969 Å was chosen for data collection
after a scan for the maximum X-ray absorption of the crystal in
proximity to the theoretical K absorption edge of bromine, and the
data-collection strategy was designed to obtain an overall multiplicity
of greater than four. Subsequent processing of the data was carried
out with the XDS software package (Kabsch, 2010) and the CCP4
program suite (Winn et al., 2011). The diffraction frames were inte-
grated with XDS and the resulting intensities were scaled with
XSCALE, in which Friedel pairs were not merged (‘FRIEDEL’S_
LAW=FALSE’ option; Table 1). The data set was phased by mole-
cular replacement with MOLREP (Vagin & Teplyakov, 2010)
employing the coordinates of PDB entry 1ydt (Engh et al., 1996).
The structure was refined with REFMAC5 (Murshudov et al., 2011;
Table 1) and the resulting structure factors were merged with the
columns ‘DANO’ and ‘SIGDANO’ of the unphased original *.mtz
file using the program CAD. The resulting *.mtz file containing both
the structure factors with phases and the anomalous signal of the
bromine of H-89 was used to calculate anomalous difference Fourier
maps with the program FFT (Ten Eyck, 1973).
REFMAC5 (Murshudov et al., 2011) was used to generate weighted
electron-density and difference maps (2mFo  DFc and mFo  DFc,
respectively) for the refined structures (Figs. 2b and 2c). Fo and Fc
refer to the observed and model structure factors, m is the figure of
merit and D is the model error parameter. The REFMAC5 calcula-
tion of the weighting factors D and m (Murshudov et al., 2011)
matches that in SIGMAA (Read, 1986) except that only the free-
R-flagged reflections are used to estimate m and D. For missing
reflections, the map coefficients are replaced with DFc in electron-
density maps and zero in difference maps.
2.3. Inhibitors
The kinase inhibitor H-89 was purchased from Cayman Chemicals
(Ann Arbor, USA). The ‘protein kinase inhibitor’ peptide (PKI;
5TTYADFIASGRTGRRNAIHD24) used in the purification and
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Table 1
Refinement and structure statistics of PDB entry 3vqh.
Values in parentheses are for the last shell.
Data collection and scaling (XDS)
X-ray source ID29, ESRF
Resolution limits (Å) 35.0–1.95 (2.20–1.95)
Unit-cell parameters (Å) a = 72.73, b = 75.18, c = 80.33
Space group P212121
Wavelength (Å) 0.91969
Total No. of reflections 283804 (84880)
No. of unique reflections 61702 (18509)
Multiplicity 4.6 (4.6)
hI/(I)i 19.08 (5.68)
Rmrgd-F† (%) 9.0 (28.8)
Completeness (%) 98.0 (99.3)




Average B factor (Å2) 21.88
No. of protein atoms 3015
No. of ligand atoms 62
No. of water molecules 178
R.m.s.d. bond lengths (Å) 0.010
R.m.s.d. bond angles () 1.38
Ramachandran plot (PROCHECK)
Most favoured (%) 91.1
Additionally allowed (%) 8.9



















Chemical structures of adenosine-50-triphosphate (ATP), Fasudil and H-89 in
similar orientations with respect to the ATP pocket (hinge region at the left). The
isoquinoline portion of H-89 is highlighted in blue, the sulfonamide portion in
green and the bromobenzene moiety in red. The numbering of the H-89 molecule
refers to C3 and N4, consistent with the designation of the atoms in the structure
3vqh. ‘PKA’ refers to cAMP-dependent protein kinase catalytic subunit  isoform 1
and ‘ROCK2’ to Rho kinase . Affinity values were taken from the literature: *,
Rajagopalan et al. (2010); †, Gassel et al. (2003); ‡, Yano et al. (2008); x, Engh et al.
(1996).
cocrystallization of PKA was purchased from GL Biochem Shanghai
Ltd (Shanghai, People’s Republic of China).
2.4. Structure deposition
The coordinates and structure factors of the PKA–H-89 complex
crystal structure described here have been deposited in the Protein
Data Bank (PDB) with accession code 3vqh.
3. Results
3.1. Overall structure
In PDB entry 3vqh the catalytic subunit  of protein kinase A
appears in its usual conformation (Fig. 3a), similar to that in reference
structures such as 1atp (Zheng et al., 1993) and 1cdk (Bossemeyer et
al., 1993) and nearly identical to an earlier structure of a PKA–H-89
complex (PDB entry 1ydt; Engh et al., 1996). The root-mean-square
deviation (r.m.s.d.) between the structures 1ydt and 3vqh is 0.33 Å.
In 3vqh the fragment 5–24 of the PKI (‘protein kinase inhibitor’)
peptide, which is routinely used for structural work on PKA as it
stabilizes the kinase domain and facilitates crystallization, occupies
the peptide-substrate site, which is formed primarily by the surface
structural communications
Acta Cryst. (2012). F68, 873–877 Pflug et al.  PKA–H-89 complex 875
Figure 2
(a) Anomalous difference Fourier maps (1.95 Å) generated to cover all atoms of the asymmetric unit in PDB entry 3vqh contoured at levels of 3, 4 and 5. (b) 2.3 Å
resolution electron-density map (grey) and difference density map (green) surrounding the compound H-89 in PDB entry 1ydt (cyan; Engh et al., 1996). (c) 1.95 Å resolution
OMIT electron-density map (grey) and anomalous difference density map (blue) carved around the two conformations of compound H-89 in PDB entry 3vqh (yellow).
Table 2









35 0.0 99 99.9 0 0
30 90.0 65.84 1.3 35 1.870
25 90.9 32.47 2.4 3 1.318
20 96.7 62.23 1.4 75 1.661
15 100.0 56.57 1.3 57 1.599
10 100.0 59.68 1.2 47 1.132
9 100.0 54.80 1.3 53 1.224
8 100.0 53.60 1.6 42 1.211
7 100.0 50.58 1.6 44 1.457
6 100.0 46.30 1.7 36 1.192
5 100.0 46.07 1.8 22 1.021
4 99.8 46.41 1.8 15 0.940
3.8 99.9 43.37 2.1 13 0.920
3.55 99.9 40.27 2.4 4 0.847
3.3 99.9 35.20 2.8 8 0.920
3.05 100.0 30.36 3.7 10 0.935
2.8 99.9 23.71 5.3 9 0.906
2.45 100.0 16.07 8.6 6 0.865
2.2 100.0 10.88 13.7 3 0.836
1.95 98.0 5.68 28.8 3 0.791
Total 99.3 19.08 9.0 6 0.867
† Anomal. Corr. is the mean correlation factor between two random subsets of
anomalous intensity differences. ‡ SigAno = [|F(+)  F()|/].
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Figure 3
(a) Overall structure of PDB entry 3vqh: a ternary complex of the catalytic subunit  of protein kinase A (PKA; white), the peptidic pseudosubstrate ‘protein kinase
inhibitor’ (PKI; grey) and the ATP-competitive inhibitor H-89 (yellow). (b) B/temperature factors of the H-89 conformers in the structure 3vqh plotted as spheres on the
respective atoms. The values are indicated for selected atoms. (c) Binding environment of the H-89 conformers in the ATP pocket of PKA in structure 3vqh. Residues
Val123, Glu127 and Asn171 form hydrogen bonds to the ligands; the bromine moieties pack against hydrophobic atoms from the side chains of Phe54 and Lys174 and some
main-chain atoms of the glycine-rich loop. The inner surface of the ATP pocket is represented in red (maximum distance of 2 Å from the inhibitor molecule).
of the -helical C-terminal lobe of the protein. The N-terminal lobe,
which is mainly comprised of a five-stranded antiparallel -sheet, is
linked covalently to the C-terminal lobe by a single peptide chain (the
hinge). Their interface forms a deep cleft which constitutes the
binding pocket for the nucleotide substrate ATP. In the structure
described here, the ATP-competitive inhibitor H-89 occupies the
ATP-binding site (Fig. 3a). As shown in Fig. 1, H-89 binds with
respect to ATP such that the isoquinoline group of H-89 occupies the
adenine-binding pocket, the sulfonamide mimics the ribose group of
ATP and the bromobenzene moiety occupies the site of the phos-
phate groups beneath the glycine-rich loop (formed by -strands 1
and 2 and the -turn that links them).
As in PDB entry 1ydt (Engh et al., 1996), the electron density for
the bromobenzene portion of H-89 is diffuse and its position is not
clearly defined (Fig. 2).
3.2. The anomalous signal describes a bivalent binding mode for
H-89
The anomalous signal of the bromine of H-89 in the collected data
set is rather weak, as is evident from the ‘Anomal. corr.’ and ‘SigAno’
parameters in Table 2, which represent the mean correlation factor
between two random subsets of anomalous intensity differences and
the mean anomalous difference in units of its estimated standard
deviation, respectively. As would be hoped for a diffraction data set
containing useful anomalous dispersion information, the anomalous
correlation (‘Anomal. corr.’) exceeds 30% and the anomalous signal
is stronger than noise (‘SigAno’ > 1), but this applies only for reso-
lutions coarser than 5 Å (Table 2). However, although the strength
of the anomalous signal is far below the requirements for a successful
SAD phasing experiment (Dauter et al., 2002), it is sufficient to
unambiguously localize the position of the bromine moiety of H-89
within the asymmetric unit (Fig. 2).
The anomalous difference Fourier maps in Fig. 2(a) display a single
strong feature in the asymmetric unit which is dominant in the maps
contoured at signal-to-noise ratios of 3 and 4 and is unique in the
map contoured at 5. This peak corresponds to the localization of
the bromine group of H-89 in the ATP pocket of PKA (Fig. 2c).
However, the anomalous density is not localized to one site but
appears spread out into two spheres of density, indicating two main
positions of the bromine moiety. This result correlates well with the
unclear electron density of the bromobenzene group of H-89 in both
the structure 1ydt (Fig. 2b; Engh et al., 1996) and the higher resolution
H-89–PKA complex structure determined in this study (Fig. 2c). In
both cases it seems that the bromobenzene group of H-89 has some
freedom to rotate about an axis running perpendicular to its benzene
ring. While the electron density alone hints at this, the anomalous
density shows distinctly preferred positions of the Br atom.
Consistent with the appearance of two peaks of similar intensity in
the anomalous difference Fourier map, the ligand H-89 was modelled
in the structure 3vqh with two alternative conformations, each with
50% occupancy. Rotation of the C3—N4 bond (Fig. 1) in the flexible
linker of H-89 and adjustment of the following dihedrals placed the
bromine moieties of the two conformers into the distinct positions
indicated by the anomalous difference map. The coordinates of the
structure were subsequently refined in REFMAC5 without positional
restraints for the ligand molecule, resulting in the conformations
presented in Fig. 2(c). In the refinement the bromobenzene moieties
of H-89 retained their distinct positions in good agreement with the
density of the anomalous difference map. The linker geometries are
correspondingly displaced relative to one another; this is in accord
with the partial weak electron density of this portion of H-89 in the
structure 3vqh (Fig. 2c). In contrast, the isoquinoline moiety of H-89
is anchored to the hinge of the kinase domain via a hydrogen bond
(Fig. 3c) and hence features the lowest temperature factors in the
ligand molecule (Fig. 3b); the adjacent sulfonamide group shows a
slight rotation. The torsion angles of the amide groups with respect
to the isoquinoline vary by 17. The protein–ligand interactions
between PKA and the two conformers differ marginally. This is true
for both the polar contacts of the linker of H-89 with PKA and the
hydrophobic contacts between the bromobenzene moiety of H-89
and the glycine-rich loop of PKA (Fig. 3c). In either case the bromine
moiety of H-89 is not involved in polar contacts to the protein and the
discrete positions of its two conformers are likely to be a consequence
of constraints imposed by the linker dihedrals.
3.3. Data quality
The diffraction data utilized for modelling the structure 3vqh
originate from a single crystal which was exposed to an X-ray dose of
approximately 7 MGy. Because neither the overall diffraction quality
nor the anomalous signal decayed during data collection, the disorder
of the bromine does not appear to result from radiation damage and
both H-89 conformers are clearly observable. Consistently, the
bromine moieties of both H-89 conformers appear electron-dense
and well observed. The lengths of the bromine–carbon bonds in the
bromobenzene moieties were both 1.9 Å, which is in good agreement
with literature values.
4. Discussion
The approach of incorporating bromine into small-molecule ligands
in order to quickly screen for binding and to subsequently efficiently
determine the binding geometry has been employed as a drug-
discovery business model (Antonysamy et al., 2008; Blaney et al., 2006;
Wolf et al., 2002). Details of its application and utility are sparse in the
scientific literature. However, this would be one approach to address
the problem of evaluating ligand flexibility in drug design (Seddon et
al., 2012). Here, we show the successful use of this approach for a very
specific application, namely the characterization of the apparently
heterogeneous binding mode of a kinase inhibitor, which was not
possible using electron-density maps (2mFo  DFc) alone.
Although the statistics showed the overall anomalous signal to only
be significant in lower resolution shells, the effects of the total signal
transformed into the real-space anomalous electron-density map
were unambiguously localized at the bromine group of H-89 with a
resolution sufficient to identify two discrete positions. This demon-
strates the utility of the approach for other related applications in
characterizing binding-mode heterogeneity and also confirms its
usefulness for applications involving weak-binding ligands or low-
affinity small-molecule fragments that may bind with only partial
occupancies.
Regarding the flexible binding mode of H-89 in the ATP pocket
of PKA, the question arises whether this information may be useful
for application in inhibitor design. In general, binding flexibility is
associated with adaptability to variation in binding sites, consistent
with the broad inhibition profile of H-89 for AGC kinases (Davies
et al., 2000; Lochner & Moolman, 2006). In order to develop H-89
towards a PKB inhibitor the linker between its aromatic moieties was
rigidified, but the selectivity of the resulting compounds was not
reported (Caldwell et al., 2008; Collins et al., 2006). An interesting
approach could be to modify the linker of H-89 to capture the two
respective binding conformations and investigate potential changes in
the target-selectivity pattern of the compounds.
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